The increase in belching typically peaks during the first two to four weeks of semaglutide therapy and often improves as your gut microbiome adapts to the medication
It also reduces the risk of inflammation and chronic diseases
Phase 3 trials ongoing as of 2026
R.LundgrenJ
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
doi: 10.1016/j.biocel.2016.07.017 41